LFMD SEC-Einreichungen - LifeMD, Inc.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

CIK

948320

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to LifeMD, Inc.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 6, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact
May 6, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 LIFEMD, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Numbe
May 6, 2026	EX-99.1	LifeMD Reports First Quarter 2026 Results Exhibit 99.1 LifeMD Reports First Quarter 2026 Results ● First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company’s guidance. ● Gross margin increased approximately 420 basis points to 88%, versus the first quarter of 2025, reflecting favorable revenue mix and lower fulfillment costs. ● Record GLP-1 patient sign-ups, wi
May 6, 2026	EX-99.2	EX-99.2 Exhibit 99.2
May 6, 2026	EX-10.3	EX-10.3 Exhibit 10.3
May 6, 2026	EX-10.4	EX-10.4 Exhibit 10.4
April 30, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 30, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
April 30, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 30, 2026	ARS	ARS LIFEMD, INC. 2025 ANNUAL REPORT LifeMD, Inc. Board of Directors and Executive Officers as of April 30, 2026 BOARD OF DIRECTORS Name Principal Occupation or Employment Justin Schreiber Chairman of the Board and Chief Executive Officer, LifeMD, Inc. John R. Strawn, Jr. Partner, Strawn Pickens LLP Dr. Joseph V. DiTrolio, M.D. Clinical Professor of Surgery, New Jersey Medical School Roberto Simon Chie
April 1, 2026	S-8	As filed with the Securities and Exchange Commission on April 1, 2026 As filed with the Securities and Exchange Commission on April 1, 2026 Registration No.
April 1, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 LifeMD, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.01 per share Other 1,017,667 $ 3.92 $ 3,989,254.64 0.0001381 $ 550.92 Total Offering Amounts:
April 1, 2026	EX-4.34	EX-4.34 Exhibit 4.34
March 18, 2026	EX-10.2	EMPLOYMENT AGREEMENT Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of March 16, 2026 (the “Effective Date”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), having corporate headquarters at 236 Fifth Avenue, Suite 400, New York, NY 10001, and Atul Kavthekar, an individual and resident of the State of Illinois with an address at 3407 Fairmont Ave, Na
March 18, 2026	EX-10.1	[signatures to follow on next page] Exhibit 10.1 March 16, 2026 Marc Benathen Re: Resignation & Transition Services Agreement Dear Marc: This letter sets forth the substance of the resignation and transition services agreement (the “Agreement”) which LifeMD, Inc. (the “Company”) is offering to you (the “Employee”) to aid in your employment transition. This Agreement will become effective on the date it has been signed by both partie
March 18, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 LIFEMD, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu
March 18, 2026	EX-99.1	LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team Exhibit 99.1 LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team NEW YORK, March 16, 2026 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of
March 10, 2026	EX-21.1	Subsidiaries of LifeMD, Inc. Exhibit 21.1 Subsidiaries of LifeMD, Inc. Subsidiary Name Jurisdiction of Incorporation LifeMD, Inc. Delaware LifeMD Pharmacy Holdings, LLC Delaware LifeMD Pharmacy Holdings 1, LLC Delaware LifeMD Pharmacy Services, LLC Delaware
March 10, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-39785 LIFEMD, INC. (E
March 9, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 LIFEMD, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num
March 9, 2026	EX-99.2	EX-99.2 Exhibit 99.2
March 9, 2026	EX-99.1	LifeMD Reports Fourth Quarter and Full Year 2025 Results Exhibit 99.1 LifeMD Reports Fourth Quarter and Full Year 2025 Results ● Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. ● Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million. ● Successfully launched oral Wegovy subsequent to year end, with over 80% of new weight management patients initiating branded therapy
January 6, 2026	EX-10.4	REVOLVING LOAN NOTE Exhibit 10.4 REVOLVING LOAN NOTE January 2, 2026 FOR VALUE RECEIVED, LIFEMD, INC., a Delaware corporation (the “Borrower”), hereby promises to pay to the order of CITIZENS BANK, N.A. (the “Lender”) or its registered assigns the unpaid principal amount of the Revolving Loans made by the Lender to the Borrower, in the amounts and at the times set forth in the Credit Agreement, dated as of January 2,
January 6, 2026	EX-10.1	CREDIT AGREEMENT dated as of January 2, 2026 LIFEMD, INC., as Borrower, CITIZENS BANK, N.A., as Lender TABLE OF CONTENTS Exhibit 10.1 CREDIT AGREEMENT dated as of January 2, 2026 among LIFEMD, INC., as Borrower, and CITIZENS BANK, N.A., as Lender TABLE OF CONTENTS Page ARTICLE 1 Definitions and Rules of Construction 1 Section 1.1 Definitions 1 Section 1.2 Classification of Loans 34 Section 1.3 Terms Generally 34 Section 1.4 Accounting Terms; GAAP. 34 Section 1.5 Rounding 35 Section 1.6 References to Time 35 Section
January 6, 2026	EX-10.2	GUARANTEE AGREEMENT LIFEMD, INC., EACH OF THE SUBSIDIARY GUARANTORS PARTY HERETO CITIZENS BANK, N.A., as Lender Dated as of January 2, 2026 TABLE OF CONTENTS Exhibit 10.2 GUARANTEE AGREEMENT among LIFEMD, INC., EACH OF THE SUBSIDIARY GUARANTORS PARTY HERETO and CITIZENS BANK, N.A., as Lender Dated as of January 2, 2026 TABLE OF CONTENTS Page Article 1. DEFINITIONS AND RULES OF CONSTRUCTION 1 Section 1.1 Credit Agreement Defined Terms 1 Section 1.2 Incorporation by Reference 2 Section 1.3 Loan Parties 2 Article 2. GUARANTEE; FRAUDULENT TRANSFER, ETC. 2
January 6, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2026 LIFEMD, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2026 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File N
January 6, 2026	EX-10.3	PLEDGE AND SECURITY AGREEMENT LIFEMD, INC., EACH OF THE GUARANTORS PARTY HERETO CITIZENS BANK, N.A., as Lender Dated as of January 2, 2026 TABLE OF CONTENTS Exhibit 10.3 PLEDGE AND SECURITY AGREEMENT among LIFEMD, INC., EACH OF THE GUARANTORS PARTY HERETO and CITIZENS BANK, N.A., as Lender Dated as of January 2, 2026 TABLE OF CONTENTS Page Article 1 DEFINITIONS AND RULES OF CONSTRUCTION 1 Section 1.1 Credit Agreement Defined Terms 1 Section 1.2 Uniform Commercial Code Terms and Provisions 1 Section 1.3 Other Defined Terms 2 Section 1.4 Incorporation B
January 6, 2026	EX-99.1	LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A. Exhibit 99.1 LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A. NEW YORK, January 6, 2026 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2
November 17, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Ex
November 17, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 LIFEMD, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
November 17, 2025	EX-99.1	LifeMD Reports Third Quarter 2025 Results Exhibit 99.1 LifeMD Reports Third Quarter 2025 Results ● Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million. ● Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million. ● Paid off all outstanding debt during the quarter ● Subsequent to quarter end, fully divested our majority stake in WorkSim
November 12, 2025	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ⌧ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.
November 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 LIFEMD, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
November 5, 2025	EX-99.1	LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17 Exhibit 99.1 LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17 NEW YORK, November 5, 2025 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 1
November 4, 2025	EX-99.1	LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform Transaction Values WorkSimpli at $65 Million Enterprise Value; Support’s LifeMD’s Strategic Focus on Scaling its Virtual Ca Exhibit 99.1 LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform Transaction Values WorkSimpli at $65 Million Enterprise Value; Support’s LifeMD’s Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses NEW YORK, November 4, 2025 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services an
November 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 LIFEMD, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Numb
November 4, 2025	EX-10.1	STOCK PURCHASE AGREEMENT dated as of November 4, 2025 by and among the Sellers (as defined herein), LIFEMD, INC., as a Seller and the Seller Representative, WORKSIMPLI SOFTWARE LLC as the Company, LION BUYER, LLC as the Purchaser TABLE OF CONTENTS Exhibit 10.1 Execution Version STOCK PURCHASE AGREEMENT dated as of November 4, 2025 by and among the Sellers (as defined herein), LIFEMD, INC., as a Seller and the Seller Representative, WORKSIMPLI SOFTWARE LLC as the Company, LION BUYER, LLC as the Purchaser TABLE OF CONTENTS Page Article I DEFINITIONS 1 Section 1.1 Definitions 1 Article II PURCHASE AND SALE; CLOSING 14 Section 2.1 Purchase and
September 10, 2025	144	144 144 0001802844 XXXXXXXX LIVE 0000948320 LifeMD, Inc. 001-39785 236 FIFTH AVENUE SUITE 400 NEW YORK NY 10001 (866) 351-5907 Alvarez Nicholas P Officer Common Charles Schwab Corp. 3000 Schwab Way Westlake TX 76262 75000 459000.00 47417393 09/10/2025 NASDAQ Common 03/01/2025 RSU Vesting Issuer N 75000 03/01/2025 N/A Y 09/10/2025 Nicholas Alvarez
August 21, 2025	EX-16.1	August 21, 2025 Exhibit 16.1 August 21, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by LifeMD, Inc. under Item 4.01 of its Form 8-K dated August 21, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of LifeMD, Inc. contained therein. Very tr
August 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 LIFEMD, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File N
August 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 LIFEMD, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu
August 5, 2025	EX-99.1	LifeMD Reports Second Quarter 2025 Results Exhibit 99.1 LifeMD Reports Second Quarter 2025 Results ● Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million ● Telehealth revenue increased 30% to $48.6 million; telehealth adjusted EBITDA rose 560% to $3.4 million ● Generated more than $8 million of operating cash flow ● Paid down $2.1 million of senior debt, exited the quarter with $36.2 millio
August 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact n
July 31, 2025	EX-10.4	Third Amendment to Employment Agreement, dated July 27, 2025 between LifeMD, Inc. and Shayna Webb Dray Exhibit 10.4 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT THIS THIRD AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Third Amendment”) is entered into as of July 27, 2025 (the “Third Amendment Effective Date”) by and between Shayna Dray, an individual and resident of the State of Rhode Island, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Corporat
July 31, 2025	EX-10.1	Confidential Offer Letter, dated April 14, 2021 between LifeMD, Inc. and Shayna Webb Dray Exhibit 10.1
July 31, 2025	8-K	Financial Statements and Exhibits, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num
July 31, 2025	EX-10.3	Second Amendment to Employment Agreement, dated May 7, 2024 between LifeMD, Inc. and Shayna Webb Dray Exhibit 10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of May 7, 2024 (the “Second Amendment Effective Date”) by and between Shayna Dray, an individual and resident of the State of Rhode Island, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Corpor
July 31, 2025	EX-99.1	LifeMD Names COO and Promotes Two Executives Exhibit 99.1 LifeMD Names COO and Promotes Two Executives NEW YORK, July 31, 2025 – LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services, today announced the appointment of Shayna Webb Dray as its Chief Operating Officer. Ms. Webb Dray, an accomplished operations and supply chain executive with over 15 years of experience, has been an integral part of LifeMD’s growth, mos
July 31, 2025	EX-10.2	First Amendment to Employment Agreement, dated November 8, 2023 between LifeMD, Inc. and Shayna Webb Dray Exhibit 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “First Amendment”) is entered into as of November 8, 2023 (the “First Amendment Effective Date”) by and between Shayna Dray, an individual and resident of the State of Rhode Island, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Corpo
July 31, 2025	EX-10.5	Restricted Stock Unit Award Agreement, dated July 27, 2025, between LifeMD, Inc. and Shayna Webb Dray Exhibit 10.5 EXHIBIT A LIFEMD, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is made as of July 27, 2025 (the “Grant Date”) between LifeMD, Inc. (the “Company”), and Shayna Dray (the “Employee”). WHEREAS, the Company desires to grant the Employee, Restricted Stock Units of the Company’s Common Stock, $0.01 par value (“RSUs”), subject to certain restrictions as set fo
June 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 LIFEMD, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num
May 6, 2025	EX-99.1	LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance Exhibit 99.1 LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance · Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70% · Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago period · Telehealth adjusted EBITDA increased to $5.3 million from a loss of $1.3 million in the year-ago period · GAAP net income of $0.6
May 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact
May 6, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Numbe
April 29, 2025	EX-99.1	Apr 28, 2025 07:00am Exhibit 99.1 Apr 28, 2025 07:00am LifeMD Acquires Women’s Health Provider Optimal Human Health MD to Accelerate Entry into the Women’s Health Market NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD (“Optimal”), a nationwide women’s health virtual c
April 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 LIFEMD, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu
April 28, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
April 28, 2025	ARS	ARS LIFEMD, INC. 2024 ANNUAL REPORT LifeMD, Inc. Board of Directors and Executive Officers as of April 28, 2025 BOARD OF DIRECTORS Name Principal Occupation or Employment Justin Schreiber Chairman of the Board and Chief Executive Officer, LifeMD, Inc. John R. Strawn, Jr. Partner, Strawn Pickens LLP Dr. Joseph V. DiTrolio, M.D. Clinical Professor of Surgery, New Jersey Medical School Roberto Simon Chie
April 25, 2025	EX-16.1	Letter from Marcum LLP, to the Securities and Exchange Commission, dated April 25, 2025. Exhibit 16.1 April 25, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by LifeMD, Inc. under Item 4.01 of its Form 8-K dated April 24, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of LifeMD, Inc., contained therein. Very tru
April 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 LIFEMD, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu
March 11, 2025	EX-19	LifeMD, Inc. Insider Trading Policy Exhibit 19 LIFEMD, INC. INSIDER TRADING POLICY This Insider Trading Policy (“Policy”) sets forth the policies of LifeMD, Inc. (the “Company”) on trading and causing the trading of securities while in possession of confidential information. Purpose The Board of Directors of the Company has adopted this Policy to provide guidance to Insiders (as defined below) about trading in the Company’s securiti
March 11, 2025	EX-10.43	Fourth Renewed Director Agreement, dated December 2, 2024, by and between LifeMD, Inc. and John Strawn Exhibit 10.43 FOURTH RENEWED DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of December 2, 2024 (the “Agreement”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), and John Strawn, an individual with an address of [***] (the “Director”). WHEREAS, the Company originally appointed the Director on April 20, 2011; re-entered into an agreement with Director for each subsequen
March 11, 2025	EX-10.68	Employment Agreement, dated December 13, 2021, between Dennis Wijnker and LifeMD, Inc. Exhibit 10.68 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of December 13th, 2021, (the “Effective Date”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), having corporate headquarters at 236 Fifth Avenue, Suite 400, New York, NY 10001, and Dennis Wijnker, an individual and resident of the State of California with an address at [***] (the “
March 11, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-39785 LIFEMD, INC. (E
March 11, 2025	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of LifeMD, Inc. Subsidiary Name Jurisdiction of Incorporation WorkSimpli Software LLC Puerto Rico
March 11, 2025	EX-10.44	Third Renewed Director Agreement, dated December 6, 2024, by and between LifeMD, Inc. and Dr. Joseph V. DiTrolio Exhibit 10.44 THIRD RENEWED DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of December 6, 2024 (the “Agreement”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), and Dr. Joseph DiTrolio, an individual with an address of [***] (the “Director”). WHEREAS, the Company originally appointed the Director on or around September 4, 2014; re-entered into an agreement with Directo
March 11, 2025	EX-10.79	Employment Agreement, dated June 20, 2023, between LifeMD, Inc. and Shane Biffar Exhibit 10.79 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of June 20, 2023, (the “Effective Date”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), having corporate headquarters at 236 Fifth Avenue, Suite 400, New York, NY 10001, and Shane Biffar, an individual and resident of the State of New York with an address at [***] (the “Employee”)
March 10, 2025	EX-99.1	LifeMD Reports Fourth Quarter 2024 Results Exhibit 99.1 LifeMD Reports Fourth Quarter 2024 Results ● Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60% ● Adjusted EBITDA increased 78% to $9.0 million ● Telehealth adjusted EBITDA increased 396% to $5.9 million ● Full-year cash flow from operations increased 99% to $17.5 million and generated positive full-year net cash flow ● Exited 2024 with
March 10, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu
February 14, 2025	LETTER	LETTER February 14, 2025 Marc Benathen Chief Financial Officer LifeMD, Inc. 236 Fifth Avenue, Suite 400 New York, New York 10001 Re: LifeMD, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 File No. 001-39785 Dear Marc Benathen: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwi
January 31, 2025	CORRESP	CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. §200.83 BY LIFEMD, INC. LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, New York 10001 CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. §200.83 BY LIFEMD, INC. LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, New York 10001 VIA FEDERAL EXPRESS AND SECURE E-MAIL January 31, 2025 Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Christie Wong Ms. Li Xiao Mr. Micha
January 17, 2025	LETTER	LETTER January 17, 2025 Marc Benathen Chief Financial Officer LifeMD, Inc. 236 Fifth Avenue, Suite 400 New York, New York 10001 Re: LifeMD, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Response Dated December 12, 2024 File No. 001-39785 Dear Marc Benathen: We have reviewed your December 12, 2024 response to our comment letter and have the following comments. Please respond to this letter wi
January 13, 2025	EX-4.38	Fourth Renewed Director Agreement, dated December 2, 2024, between LifeMD, Inc. and John Strawn Exhibit 4.38
January 13, 2025	EX-4.12	Second Amendment to Employment Agreement by and between Stefan Galluppi and LifeMD, Inc., dated November 15, 2021 Exhibit 4.12
January 13, 2025	S-8	As filed with the Securities and Exchange Commission on January 13, 2025 As filed with the Securities and Exchange Commission on January 13, 2025 Registration No.
January 13, 2025	EX-4.36	Second Renewed Director Agreement, dated November 22, 2022, between LifeMD, Inc. and John Strawn Exhibit 4.36
January 13, 2025	EX-4.24	Second Amendment to Employment Agreement, dated November 7, 2023, between Maria Stan and LifeMD, Inc. Exhibit 4.24
January 13, 2025	EX-4.41	Third Renewed Director Agreement, dated December 6, 2024, by and between LifeMD, Inc. and Dr. Joseph DiTrolio Exhibit 4.41
January 13, 2025	EX-4.30	First Amendment to the Employment Agreement, dated August 18, 2024, between Dennis Wijnker and LifeMD, Inc. Exhibit 4.30
January 13, 2025	EX-4.33	Third Renewed Director Agreement, dated August 21, 2023, by and between LifeMD, Inc. and Roberto Simon Exhibit 4.33
January 13, 2025	EX-4.14	Fourth Amendment to Employment Agreement by and between Stefan Galluppi and LifeMD, Inc., dated October 12, 2023 Exhibit 4.14
January 13, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) LIFEMD, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities
January 13, 2025	EX-4.44	Second Amendment to the Director Agreement, dated December 20, 2024, between Dr. Joan LaRovere and LifeMD, Inc. Exhibit 4.44
January 13, 2025	EX-4.34	Fourth Renewed Director Agreement, dated December 2, 2024, by and between LifeMD, Inc. and Roberto Simon Exhibit 4.34
January 13, 2025	EX-4.11	First Amendment to Employment Agreement by and between Stefan Galluppi and Conversion Labs, Inc., dated April 1, 2020 Exhibit 4.11
January 13, 2025	EX-4.43	First Amendment to the Director Agreement, dated January 20, 2024, between Dr. Joan LaRovere and LifeMD, Inc. Exhibit 4.43
January 13, 2025	EX-4.32	Second Renewed Director Agreement, dated July 1, 2022, by and between LifeMD, Inc. and Roberto Simon Exhibit 4.32
January 13, 2025	EX-4.29	Employment Agreement, dated December 13, 2021, between LifeMD, Inc. and Dennis Wijnker Exhibit 4.29
January 13, 2025	EX-4.13	Third Amendment to Employment Agreement by and between Stefan Galluppi and LifeMD, Inc., dated December 28, 2021 Exhibit 4.13
January 13, 2025	EX-4.37	Third Renewed Director Agreement, dated August 25, 2023, between LifeMD, Inc. and John Strawn Exhibit 4.37
January 13, 2025	EX-4.40	Second Renewed Director Agreement, dated November 22, 2022, by and between LifeMD, Inc. and Dr. Joseph DiTrolio Exhibit 4.40
December 31, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2024 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
December 31, 2024	EX-10.1	Second Amendment dated December 24, 2024 to the Employment Agreement between Justin Schreiber and LifeMD, Inc. Exhibit 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of December 24, 2024 (the “Second Amendment Effective Date”) by and between Justin Schreiber, an individual and resident of the State of Pennsylvania, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Dela
December 23, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
December 12, 2024	CORRESP	CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. §200.83 BY LIFEMD, INC. LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, New York 10001 CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. §200.83 BY LIFEMD, INC. LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, New York 10001 VIA FEDERAL EXPRESS AND SECURE E-MAIL December 12, 2024 Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Christie Wong Mr. Michael Fay Re:
November 22, 2024	LETTER	LETTER November 22, 2024 Marc Benathen Chief Financial Officer LifeMD, Inc. 236 Fifth Avenue, Suite 400 New York, New York 10001 Re: LifeMD, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Response Dated October 25, 2024 File No. 001-39785 Dear Marc Benathen: We have reviewed your October 25, 2024 response to our comment letter and have the following comments. Please respond to this letter wit
November 14, 2024	SC 13G/A	LFMD / LifeMD, Inc. / Divisadero Street Capital Management, LP Passive Investment SC 13G/A 1 d1152814813g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* LifeMD, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 53216B104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
November 8, 2024	SC 13G	LFMD / LifeMD, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us53216b1044110824.txt us53216b1044110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) LIFEMD INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 53216B104 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Ex
November 7, 2024	EX-10.6	First Amendment to Consulting Services Agreement, dated July 17, 2024, by and between LifeMD, Inc. and Robert Jindal Exhibit 10.6 FIRST AMENDMENT TO CONSULTING SERVICES AGREEMENT This First Amendment To Consulting Services Agreement (“First Amendment”) is made effective as of July 17, 2024 (the “First Amendment Effective Date”), by and between Robert Jindal, having an address at [***] (the “Consultant”) and LifeMD, Inc., a corporation with an address of 236 Fifth Avenue, Suite 400, New York, NY 10001 (the “Compa
November 7, 2024	EX-10.4	First Amendment to Office Lease Agreement, dated May 6, 2024, by and between 236 Fifth Leasehold, LLC and LifeMD, Inc. Exhibit 10.4 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE dated as of May 6th, 2024 (this “Amendment”) between 236 FIFTH LEASEHOLD LLC, a Delaware limited liability company having an office c/o Kaufman Management Company, LLC, 450 Seventh Avenue, New York, New York 10123 (“Landlord”), and LIFEMD, INC., a Delaware corporation having an office at 236 Fifth Avenue, New York, New York 10001
November 7, 2024	EX-10.3	Second Amendment to Warehouse Lease Agreement, dated February 20, 2024, by and between Running Pump Business Center, LLC and LifeMD Pharmacy Services, LLC Exhibit 10.3 SECOND AMENDMENT TO THE LEASE AGREEMENT (“AGREEMENT”) BETWEEN Running Pump Business Center, LP, “LANDLORD” AND LifeMD, “TENANT” FOR A PORTION OF THE PROPERTY AT 499 Running Pump Road Township of East Hempfield DATED February 20, 2024 It is mutually understood and agreed by all parties that this Agreement shall be amended as follows: 1. “TENANT” party is now identified with increased s
November 7, 2024	EX-10.1	Warehouse Lease Agreement, dated February 20, 2024, by and between Running Pump Business Center, LLC and LifeMD, Inc. EX-10.1 2 ex10-1.htm Exhibit 10.1 LEASE AGREEMENT This Lease (“Lease”) is made and entered into as of February 20, 2024 (the “Effective Date”) by and between the Landlord and the Tenant named below. ARTICLE 1. Definitions and Certain Basic Provisions. 1.1 (a) “Landlord”: RUNNING PUMP BUSINESS CENTER, LP, a Pennsylvania Limited Partnership (b) “Managing Agent”: Running Pump Business Center, LLC (c)
November 7, 2024	EX-10.5	201 Brookfield Parkway Lease Agreement, dated September 17, 2024, by and between Front Street - Brookfield, LLC and LifeMD, Inc. Exhibit 10.5 OFFICE LEASE ******************************* FRONT STREET - BROOKFIELD, LLC (Lessor) and LIFEMD, INC. (Lessee) TABLE OF CONTENTS Paragraph Number Subject Page 1 Tenant Improvements 1 2 Lease Term; Security Deposit 2 3 Rental 3 4 Maintenance Responsibilities; Operating Expenses 5 5 Taxes & Assessments 6 6 Services by Lessor 7 7 Alterations 7 8 Use and Occupancy 8 9 Insurance 9 10 Fire
November 7, 2024	EX-10.2	First Amendment to Warehouse Lease Agreement, dated February 20, 2024, by and between Running Pump Business Center, LLC and LifeMD, Inc. Exhibit 10.2 FIRST AMENDMENT TO THE LEASE AGREEMENT (“AGREEMENT”) BETWEEN Running Pump Business Center, LP, “LANDLORD” AND LifeMD, “TENANT” FOR A PORTION OF THE PROPERTY AT 499 Running Pump Road Township of East Hempfield DATED February 20, 2024 It is mutually understood and agreed by all parties that this Agreement shall be amended as follows: 1. In addition to the Tenant Work outlined in Article
October 31, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 LIFEMD, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
October 25, 2024	CORRESP	LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, New York 10001 LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, New York 10001 October 25, 2024 VIA EDGAR SUBMISSION Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Christie Wong Mr. Michael Fay Re: LifeMD, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 File No. 001-39785 Dear
October 24, 2024	SC 13G	LFMD / LifeMD, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us53216b1044102424.txt us53216b1044102424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) LIFEMD INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 53216B104 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
October 16, 2024	LETTER	LETTER October 16, 2024 Marc Benathen Chief Financial Officer LifeMD, Inc. 236 Fifth Avenue, Suite 400 New York, New York 10001 Re: LifeMD, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 File No. 001-39785 Dear Marc Benathen: We have limited our review of your filing to the financial statements and related disclosures and have the following comments. Please respond to this letter within ten b
August 13, 2024	424B3	LIFEMD, INC. 1,284,892 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279860 PROSPECTUS LIFEMD, INC. 1,284,892 Shares of Common Stock This prospectus relates to the resale (the “Offering”), from time to time, of up to 1,284,892 shares (the “Shares”) of our common stock, par value $0.01 per share (“Common Stock”), held by the Selling Stockholders identified in this prospectus under “Selling Stockholders”. 1,224,42
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact n
July 16, 2024	CORRESP	LifeMD, Inc. 226 Fifth Avenue, Suite 400 New York, NY 10001 LifeMD, Inc. 226 Fifth Avenue, Suite 400 New York, NY 10001 July 16, 2024 VIA EDGAR U.S. Securities & Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Juan Grana Re: LifeMD, Inc. Registration Statement on Form S-3, as amended Filed May 31, 2024 File No. 333-279860 Dear Mr. Grana: In accordance with Rule 461 of the Securities Act of 1933, as a
July 16, 2024	CORRESP	LifeMD, Inc. 226 Fifth Avenue, Suite 400 New York, NY 10001 LifeMD, Inc. 226 Fifth Avenue, Suite 400 New York, NY 10001 July 16, 2024 VIA EDGAR U.S. Securities & Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Juan Grana Re: LifeMD, Inc. Registration Statement on Form S-3, as amended Filed June 7, 2024 File No. 333-280033 Dear Mr. Grana: In accordance with Rule 461 of the Securities Act of 1933, as a
July 5, 2024	S-8	As filed with the Securities and Exchange Commission on July 5, 2024 As filed with the Securities and Exchange Commission on July 5, 2024 Registration No.
July 5, 2024	S-3/A	As filed with the Securities and Exchange Commission on July 5, 2024 As filed with the Securities and Exchange Commission on July 5, 2024 Registration No.
July 5, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) LIFEMD, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities
July 5, 2024	EX-4.6	Description of verbal agreement between Immudyne, Inc. and Strawn Pickens LLP dated March 9, 2012 Exhibit 4.6 Description of Verbal Agreement between Immudyne, Inc. and Strawn Pickens LLP John R. Strawn, Jr., is a founding partner of Strawn Pickens LLP. During 2011, Strawn Pickens LLP provided legal services to Immudyne, Inc., a predecessor of LifeMD, Inc. On March 9, 2012, Immudyne issued 80,000 shares to Strawn Pickens LLP in settlement of $70,000 in outstanding fees for these legal services
July 5, 2024	S-3/A	As filed with the Securities and Exchange Commission on July 5, 2024 As filed with the Securities and Exchange Commission on July 5, 2024 Registration No.
July 5, 2024	EX-4.5	Power of Attorney and Contingent Fee Contract between Immudyne, Inc. and Cruse Scott Henderson & Allen LLP dated August 9, 2004 Exhibit 4.5
June 18, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num
June 18, 2024	EX-10.1	Third Amended and Restated 2020 Equity and Incentive Plan Exhibit 10.1 LIFEMD, INC. THIRD AMENDED AND RESTATED 2020 EQUITY AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN: DEFINITIONS The name of the plan is the LIFEMD, INC. THIRD AMENDED AND RESTATED 2020 EQUITY AND INCENTIVE PLAN (the “Plan”). The purpose of the Plan is to encourage, retain and enable the officers, employees, directors, Consultants and other key persons of LIFEMD, INC., a Del
June 17, 2024	LETTER	LETTER United States securities and exchange commission logo June 17, 2024 Justin Schreiber Chief Executive Officer LifeMD, Inc.
June 10, 2024	LETTER	LETTER United States securities and exchange commission logo June 10, 2024 Justin Schreiber Chief Executive Officer LifeMD, Inc.
June 7, 2024	S-3	As filed with the Securities and Exchange Commission on June 7, 2024 As filed with the Securities and Exchange Commission on June 7, 2024 Registration No.
June 7, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) LIFEMD, INC. (Exact name of registrant as specified in its charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly
May 31, 2024	EX-4.12	Registration Rights Agreement between LifeMD, Inc. and Jason Pharmaceuticals, Inc., dated December 11, 2023 Exhibit 4.12 Execution Copy REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 11, 2023, is made and entered into by and between LifeMD, Inc., a Delaware corporation (the “Company”) and Jason Pharmaceuticals, Inc., a Maryland corporation (“Holder”). RECITALS WHEREAS, pursuant to the terms of that certain Stock Purchase Agreement (the “Purchase
May 31, 2024	EX-4.11	Stock Purchase Agreement between LifeMD, Inc. and Jason Pharmaceuticals, Inc., dated December 11, 2023 Exhibit 4.11 Execution Copy STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”) is dated as of December 11, 2023, between LifeMD, Inc., a Delaware corporation (the “Company”), and Jason Pharmaceuticals, Inc., a Maryland corporation (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to
May 31, 2024	S-3	As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No.
May 31, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) LIFEMD, INC. (Exact name of registrant as specified in its charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly
May 24, 2024	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact
May 2, 2024	EX-10.1	Director Agreement, dated April 26, 2024, between LifeMD, Inc. and Calum MacRae Exhibit 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of April 26, 2024 (the “Agreement”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), and Dr. Calum MacRae, an individual with an address of 34 Yarmouth Road, Wellesley Hills, MA 02481 (the “Director”). WHEREAS, the Company and the Director desire to enter with respect to the appointment of the Director; WHEREAS
May 2, 2024	EX-99.1	LifeMD Appoints Dr. Calum MacRae to its Board of Directors Exhibit 99.1 LifeMD Appoints Dr. Calum MacRae to its Board of Directors NEW YORK, April 29, 2024 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. “We are delighted to welcome Dr. MacRae t
May 2, 2024	EX-10.2	Restricted Stock Award Agreement, dated April 26, 2024, between LifeMD, Inc. and Calum MacRae Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT DIRECTORS THIS RESTRICTED STOCK AWARD (this “Agreement”) is granted as of April 26, 2024 (the “Grant Date”), and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the “Agreement”) between LifeMD, Inc. (the “Company”), and Dr. Calum MacRae (the “Director”). WHEREAS, the Company desires to grant the Director, shares of the Company’s Common
May 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 LIFEMD, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu
April 29, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 29, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 29, 2024	ARS	ARS LIFEMD, INC. 2023 ANNUAL REPORT LifeMD, Inc. Board of Directors and Executive Officers as of April 29, 2024 BOARD OF DIRECTORS Name Principal Occupation or Employment Justin Schreiber Chairman of the Board of Directors, LifeMD, Inc. Chief Executive Officer, LifeMD, Inc. John R. Strawn, Jr. Partner, Strawn Pickens LLP Dr. Joseph V. DiTrolio, MD Clinical Professor of Surgery, New Jersey Medical Scho
March 15, 2024	S-8	As filed with the Securities and Exchange Commission on March 15, 2024 As filed with the Securities and Exchange Commission on March 15, 2024 Registration No.
March 15, 2024	EX-4.19	Confidential Employment Term Sheet, dated June 23, 2020, between Kevin Veal and LifeMD, Inc. Exhibit 4.19
March 15, 2024	EX-4.20	First Amendment to Employment Agreement, dated July 5, 2021, between Kevin Veal and LifeMD, Inc. Exhibit 4.20
March 15, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) LIFEMD, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securit
March 15, 2024	EX-4.17	Stock Option Agreement, dated April 20, 2011, between ImmuDyne, Inc. and John R. Strawn Exhibit 4.17
March 15, 2024	EX-4.18	Stock Option Agreement, dated April 20, 2011, between ImmuDyne, Inc. and John R. Strawn Exhibit 4.18
March 11, 2024	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of LifeMD, Inc. Subsidiary Name Jurisdiction of Incorporation WorkSimpli Software LLC Puerto Rico Cleared Technologies, PBC Delaware Springbox Technologies LLC Delaware Taylor Technologies Inc Delaware
March 11, 2024	EX-10.110	Separation Agreement dated March 9, 2024 between Brad Roberts and LifeMD, Inc. Exhibit 10.110
March 11, 2024	EX-97.DESCRIBTION	Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97
March 11, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39785 LIFEMD, INC. (E
February 14, 2024	SC 13G/A	LFMD / LifeMD, Inc. / Divisadero Street Capital Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
December 21, 2023	EX-4.27	Employment Agreement, dated December 13, 2021, between LifeMD, Inc. and Dennis Wijnker Exhibit 4.27 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of December 13th, 2021, (the “Effective Date”), by and between LifeMD, Inc., a Delawa
December 21, 2023	EX-4.16	Stock Option Agreement, dated January 2, 2017, between ImmuDyne, Inc. and John R. Strawn Exhibit 4.16 STOCK OPTION AGREEMENT THIS AGREEMENT is entered into this 2nd day of January, 2017 between ImmuDyne, Inc., a Delaware corporation (the “Company”) and John R. Strawn (“Option Holder/Holder”). WHEREAS, the Board of Directors of the Company has this day authorized the issuance of the option set forth below to Option Holder. NOW, THEREFORE, in consideration of the mutual covenants herein
December 21, 2023	EX-4.25	Non-Qualified Stock Option Agreement, dated October 8, 2021, between LifeMD, Inc. and John V. McMillin IV Exhibit 4.25 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT EMPLOYEE THIS NON-QUALIFIED STOCK OPTION AGREEMENT (the “Agreement”) entered into as of the October 8, 2021 (the “Mem
December 21, 2023	S-8	As filed with the Securities and Exchange Commission on December 21, 2023 As filed with the Securities and Exchange Commission on December 21, 2023 Registration No.
December 21, 2023	EX-4.21	Conversion Labs, Inc. Confidential Employment Offer Letter, dated August 1, 2020, between Conversion Labs, Inc. and Stephanie Sumell Exhibit 4.21 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. As of August 1st, 2020 CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT OFFER Set forth below is an outline of the management compensation terms by which the undersigned
December 21, 2023	EX-4.19	Employment Agreement, dated October 1, 2019, between Conversion Labs, Inc. and Ernie Ibarra Exhibit 4.19 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), effective as of October 1, 2019, is entered into between Conversion Labs, Inc., a Delaware corporati
December 21, 2023	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) LIFEMD, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securit
December 21, 2023	EX-4.26	Non-Qualified Stock Option Agreement, dated November 9, 2021, between LifeMD, Inc. and Kenny Bae Exhibit 4.26 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT EMPLOYEE THIS NON-QUALIFIED STOCK OPTION AGREEMENT (the “Agreement”) entered into as of the November 9, 2021 (the “Me
December 21, 2023	EX-4.22	Conversion Labs, Inc. Confidential Employment Term Sheet, dated August 28, 2020, between Conversion Labs, Inc. and Tucker Crisfield Exhibit 4.22 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT TERM SHEET Set forth below is an outline of the compensation terms by which the undersigned parties agree to abide by whe
December 21, 2023	EX-4.29	Employment Agreement, dated October 1, 2019, between Conversion Labs, Inc. and Michael Angulo Exhibit 4.29 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), effective as of October 1, 2019, is entered into between Conversion Labs, Inc., a Delaware corporati
December 21, 2023	EX-4.23	Conversion Labs, Inc. Confidential Employment & Investment Term Sheet, dated September 28, 2020, between Conversion Labs, Inc. and Michael Scully Exhibit 4.23 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. As of September 28th, 2020 CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT & INVESTMENT TERM SHEET Set forth below is an outline of the management compensation terms by
December 21, 2023	EX-4.28	Bonus Agreement, between August 16, 2017, between ImmuDyne, Inc. and Brian Schreiber DBA BV Global Fulfillment, LLC Exhibit 4.28 BONUS AGREEMENT This AGREEMENT (“Agreement’’) is dated as of August 16, 2017 between IMMUDYNE, INC., a Delaware corporation (the “Company”), and Brian Schreiber DBA BV Global Fulfillment, LLC (“Independent Contractor’’). The Company and the Independent Contractor are hereinafter sometimes referred to collectively as the “Parties” and individually as a “Party.” WITNESSETH: WHEREAS, the
December 21, 2023	EX-4.20	Conversion Labs, Inc. Confidential Employment & Investment Term Sheet, dated February 10, 2020, between Conversion Labs, Inc. and Kenny Bae Exhibit 4.20 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. As of February 10th, 2020 CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT & INVESTMENT TERM SHEET Set forth below is an outline of the management compensation terms by w
December 21, 2023	EX-4.18	Conversion Labs, Inc. Confidential Employment Offer Letter, dated September 10, 2018, between Conversion Labs, Inc. and Ernie Ibarra Exhibit 4.18 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [*] indicates that information has been omitted. September 10, 2018 CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT OFFER LETTER Name: Ernie Ibarra (the “Employee”) Position: Lead Web Developer Base Salary: $[*] from
December 21, 2023	EX-4.24	Conversion Labs, Inc. Confidential Employment Term Sheet, dated December 1, 2020, between Conversion Labs, Inc. and Ryan Norton Exhibit 4.24 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT TERM SHEET Set forth below is an outline of the compensation terms by which the undersigned parties agree to abide by whe
December 13, 2023	EX-99.1	LifeMD and Medifast Partner to Offer Transformative Weight Management Solution Collaboration will integrate LifeMD’s telehealth platform and GLP-1 offering for medically qualified patients with OPTAVIA Coach-guided, healthy lifestyle solution Medifas Exhibit 99.1 LifeMD and Medifast Partner to Offer Transformative Weight Management Solution Collaboration will integrate LifeMD’s telehealth platform and GLP-1 offering for medically qualified patients with OPTAVIA Coach-guided, healthy lifestyle solution Medifast has invested $20 million, including a $10 million payment in support of the collaboration and a $10 million purchase of LifeMD common s
December 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 LIFEMD, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
November 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 LIFEMD, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
November 14, 2023	EX-10.3	Restricted Stock Award Agreement dated November 13, 2023 between Justin Schreiber and LifeMD, Inc. Exhibit 10.3 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is made effective as of November 13, 2023 (the “Grant Date”) between LifeMD, Inc. (the “Company”) and Justin Schreiber (the “Employee”). WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common Stock, $0.01 par value (“Shares”), subject to certain restrictions as set forth in this
November 14, 2023	EX-10.2	First Amendment dated November 13, 2023 to the Employment Agreement between Justin Schreiber and LifeMD, Inc. Exhibit 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “First Amendment”) is entered into as of November 13, 2023 (the “First Amendment Effective Date”) by and between Justin Schreiber, an individual and resident of the State of Pennsylvania, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware
November 14, 2023	EX-10.1	Employment Agreement dated April 1, 2022 between Justin Schreiber and LifeMD, Inc. Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of April 1, 2022, (the “Effective Date”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), having corporate headquarters at 236 Fifth Avenue, Suite 400, New York, NY 10001, and Justin Schreiber, an individual and resident of Puerto Rico with an address at 12 Dorado Beach East, Dorado,
November 8, 2023	EX-10.3	Amended and Restated First Amendment dated July 26, 2023 to the Amended and Restated Employment Agreement between Nicholas Alvarez and LifeMD, Inc. Exhibit 10.3 AMENDED AND RESTATED FIRST AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED FIRST AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amended and Restated First Amendment”) is entered into as of July 26, 2023 (the “Amended and Restated First Amendment Effective Date”) by and between Nicholas Alvarez, an individual and resident of the S
November 8, 2023	EX-1.1	First Amendment dated September 26, 2023 to the Credit Agreement among Avenue Venture Opportunities Fund II, L.P., Avenue Venture Opportunities Fund, L.P. and LifeMD, Inc. Exhibit 1.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT AND SUPPLEMENT This First Amendment to Loan and Security Agreement and Supplement (this “Amendment”) is dated as of September 26, 2023, and is entered into by and among LIFEMD, Inc., a Delaware corporation (the “Borrower”) and AVENUE VENTURE OPPORTUNITIES FUND II, L.P., (“Avenue 2”), as a lender, and AVENUE VENTURE OPPORTUNITIES FUND, L.P.
November 8, 2023	EX-10.4	Restricted Stock Award Agreement dated July 26, 2023 between Nicholas Alvarez and LifeMD, Inc Exhibit 10.4 LIFEMD, INC. AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENT THIS AMENDED AND RESTATED AGREEMENT (this “Amended Agreement”) is made effective as of July 26, 2023 (the “Grant Date”) between LifeMD, Inc. (the “Company”) and Nicholas Alvarez (the “Employee”). WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common Stock, $0.01 par value (“Shares”), subjec
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Ex
October 6, 2023	SC 13G	LFMD / LifeMD Inc / Divisadero Street Capital Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 LIFEMD, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction (Commission (IRS Employer of incorpor
August 10, 2023	EX-99.1	Investor Presentation dated August 2023 Exhibit 99.1
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact n
August 9, 2023	EX-10.4	Consulting Services Agreement, dated June 14, 2023, by and between the Company and Naveen Bhatia Exhibit 10.4 SECOND CONSULTING SERVICES AGREEMENT This Second Consulting Services Agreement (“Consulting Agreement” or the “Agreement”) is made effective as of June 14, 2023 (the “Effective Date”), by and between Naveen Bhatia, an individual with an address at 1327 Bay Head Road, Annapolis, MD 21409 (the “Consultant”) and LifeMD, Inc., a corporation with an address of 236 Fifth Avenue, Suite 400,
August 9, 2023	EX-10.1	Third Amendment to Amended and Restated Employment Agreement, dated June 13, 2023, by and between the Company and Brad Roberts Exhibit 10.1 THIRD AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS THIRD AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Third Amendment”) is entered into as of June 13, 2023 (the “Third Amendment Effective Date”) by and between Brad Roberts, an individual and resident of the State of South Carolina, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion
August 9, 2023	EX-10.3	Director and Officer Indemnification Agreement between Brad Roberts and LifeMD, Inc. dated June 13, 2023 Exhibit 10.3 EXHIBIT A LIFEMD, INC. DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT This Director and Officer Indemnification Agreement, dated as of June 13, 2023 (the “Agreement”), is made by and between LifeMD, Inc., a Delaware corporation (the “Company”), and Brad Roberts (the “Indemnitee”). RECITALS: A. The Delaware General Corporation Law provides that the business and affairs of a corporation
August 9, 2023	EX-10.5	Consulting Services Agreement, dated June 14, 2023, by and between the Company and Robert Jindal Exhibit 10.5 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (“Consulting Agreement” or the “Agreement”) is made effective as of June 14, 2023 (the “Effective Date”), by and between Robert Jindal, having an address at 15040 Audubon Lakes Drive, Baton Rouge, LA 70810 (the “Consultant”) and LifeMD, Inc., a corporation with an address of 236 Fifth Avenue, Suite 400, New York, NY 1000
August 9, 2023	EX-10.2	Restricted Stock Award Agreement dated June 13, 2023 between Brad Roberts and LifeMD, Inc. Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is entered into as of June 13, 2023 (the “Memorial Date”) between LifeMD, Inc. (the “Company”) and Brad Roberts (the “Employee”) memorializing the grant of restricted stock to Employee as set forth below (the “Grant Date”) WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common S
July 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 LIFEMD, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction (Commission (IRS Employer of incorpora
July 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 LIFEMD, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction (Commission (IRS Employer of incorpora
July 14, 2023	EX-10.3	Second Amendment dated July 11, 2023 to the Employment Agreement between Marc Benathen and LifeMD, Inc. Exhibit 10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of July 11, 2023 (the “Second Amendment Effective Date”) by and between Marc Benathen, an individual and resident of the State of New York, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Corpor
July 14, 2023	EX-10.4	Restricted Stock Award Agreement dated July 11, 2023 between Marc Benathen and LifeMD, Inc Exhibit 10.4 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is made effective as of July 11, 2023 (the “Grant Date”) between LifeMD, Inc. (the “Company”) and Marc Benathen (the “Employee”). WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common Stock, $0.01 par value (“Shares”), subject to certain restrictions as set forth in this Agreem
July 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 LIFEMD, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num
June 29, 2023	424B5	COMMON STOCK Prospectus Supplement dated June 29, 2023 Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated June 22, 2021) Registration No.
June 22, 2023	EX-10.1	Director Agreement, dated June 20, 2023 between LifeMD, Inc. and William J. Febbo Exhibit 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of June 20, 2023 (the “Agreement”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), and William Febbo, an individual with an address of 142 Calle Violeta, San Juan, Puerto Rico 00927 (the “Director”). WHEREAS, the Company and the Director desire to enter with respect to the appointment of the Director; WHEREAS,
June 22, 2023	EX-10.4	Consulting Services Agreement, dated May 30, 2023, between LifeMD, Inc. and William J. Febbo Exhibit 10.4 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (“Consulting Agreement” or the “Agreement”) is made effective as of May 30, 2023 (the “Effective Date”), by and between William Febbo, having an address at 142 Calle Violeta, San Juan, Puerto Rico 00927 (the “Consultant”) and LifeMD, Inc., a corporation with an address of 236 Fifth Avenue, Suite 400, New York, NY 10001 (
June 22, 2023	EX-10.3	Non-Qualified Stock Option Agreement, dated June 20, 2023, between LifeMD, Inc. and William J. Febbo Exhibit 10.3 LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT DIRECTOR THIS NON-QUALIFIED STOCK OPTION is granted as of June 20, 2023 (the “Grant Date”), and reflected in this NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) by and between LifeMD, Inc. (the “Company”) and William Febbo the “Optionee”). WHEREAS, pursuant to the authority of the Board of Directors (the “Board”), the Company
June 22, 2023	EX-10.2	Restricted Stock Award Agreement, dated June 20, 2023, between LifeMD, Inc. and William J. Febbo Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT DIRECTORS THIS RESTRICTED STOCK AWARD (this “Agreement”) is granted as of June 20, 2023 (the “Grant Date”), and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the “Agreement”) between LifeMD, Inc. (the “Company”), and William Febbo (the “Director”). WHEREAS, the Company desires to grant the Director, shares of the Company’s Common Sto
June 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 LIFEMD, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num
June 22, 2023	EX-99.1	LifeMD Appoints William J. Febbo to its Board of Directors Exhibit 99.1 LifeMD Appoints William J. Febbo to its Board of Directors NEW YORK, June 20, 2023 – LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (Nasdaq: OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-ca
June 20, 2023	EX-10.4	Restricted Stock Award Agreement dated June 15, 2023 between Eric Yecies and LifeMD, Inc Exhibit 10.4 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is entered into as of June 15, 2023 (the “Memorial Date”) between LifeMD, Inc. (the “Company”) and Eric H. Yecies (the “Employee”) memorializing the grant of restricted stock to Employee as set forth below (the “Grant Date”) WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common
June 20, 2023	EX-10.3	Second Amendment dated June 15, 2023 to the Employment Agreement between Eric Yecies and LifeMD, Inc. Exhibit 10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of June 15, 2023 (the “Second Amendment Effective Date”) by and between Eric H. Yecies, an individual and resident of the State of New Jersey, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Cor
June 20, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num
May 12, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 28, 2023	ARS	ARS LIFEMD, INC. 2022 ANNUAL REPORT LifeMD, Inc. Board of Directors and Executive Officers as of April 24, 2023 BOARD OF DIRECTORS Name Principal Occupation or Employment Justin Schreiber Chairman of the Board of Directors, LifeMD, Inc. Chief Executive Officer, LifeMD, Inc. Stefan Galluppi Chief Innovation Officer, LifeMD, Inc. John Strawn, Jr. Partner, Strawn Pickens LLP Dr. Joseph V. DiTrolio, MD Cl
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 27, 2023	424B5	COMMON STOCK PROSPECTUS SUPPLEMENT DATED MARCH 27, 2023 Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated June 22, 2021) Registration No.
March 23, 2023	EX-10.1	Loan and Security Agreement among LifeMD, Inc., Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P., dated March 21, 2023 EX-10.1 2 ex10-1.htm Exhibit 10.1 LOAN AND SECURITY AGREEMENT Dated as of March 21, 2023 between LIFEMD, INC., a Delaware corporation as “Borrower”, and AVENUE VENTURE OPPORTUNITIES FUND II, L.P., a Delaware limited partnership, (“Avenue 2”), as a lender, and AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (“Avenue”) as administrative agent and collateral agent (in such cap
March 23, 2023	EX-10.2	Supplement to Loan and Security Agreement among LifeMD, Inc., Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P., dated March 21, 2023 Exhibit 10.2 SUPPLEMENT to the Loan and Security Agreement dated as of March 21, 2023 among LifeMD, Inc. (“Borrower”) Avenue Venture Opportunities Fund, L.P. II, L.P., a Delaware limited partnership (“Avenue 2”), as a lender and Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership (“Avenue” and, in its capacity as a lender, together with Avenue 2, each a “Lender” and collectivel
March 23, 2023	EX-10.4	Form of Promissory Note issued to Avenue Venture Opportunities Exhibit 10.4 PROMISSORY NOTE [Note No. ] $ March 21, 2023 The undersigned (“Borrower”) promises to pay to the order of (“Lender”), at such place as Lender may designate in writing, in lawful money of the United States of America, the principal sum of Nine Million Dollars ($), with interest thereon from the date hereof until maturity, whether scheduled or accelerated, at a variable rate per annum e
March 23, 2023	EX-99.1	LifeMD, Inc. Announces Closing of New $40 Million Credit Facility Exhibit 99.1 LifeMD, Inc. Announces Closing of New $40 Million Credit Facility NEW YORK, March 22, 2023 — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that the Company closed on a new senior secured credit facility with Avenue Capital. The credit agreement, which matures on October 1, 2026, provides up to $40 million in total term loan capital includ
March 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 LIFEMD, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu
March 23, 2023	EX-10.3	Form of Warrant issued to Avenue Venture Opportunities Exhibit 10.3 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) AN OP
March 22, 2023	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of LifeMD, Inc. Subsidiary Name Jurisdiction of Incorporation WorkSimpli Software LLC Puerto Rico Conversion Labs PR LLC Puerto Rico Cleared Technologies, PBC Delaware Springbox Technologies LLC Delaware Taylor Technologies Inc Delaware
March 22, 2023	EX-10.83	Restricted Stock Award Agreement between Jessica Friedeman and LifeMD, Inc. dated January 3, 2023 Exhibit 10.83 EXHIBIT A LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is made as of January 3, 2023 (the “Grant Date”) between LifeMD, Inc. (the “Company”) and Jessica Friedeman (the “Employee”). WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common Stock, $0.01 par value (“Shares”), subject to certain restrictions as set forth in this
March 22, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39785 LIFEMD, INC. (E
March 22, 2023	EX-10.82	Employment Agreement between Jessica Friedeman and LifeMD, Inc. dated January 3, 2023 Exhibit 10.82 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of January 3, 2023, (the “Effective Date”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), having corporate headquarters at 236 Fifth Avenue, Suite 400, New York, NY 10001, and Jessica Friedeman, an individual and resident of the State of New York with an address at 38 Hallmam Road
March 22, 2023	EX-10.84	Director and Officer Indemnification Agreement between Jessica Friedeman and LifeMD, Inc. dated January 3, 2023 EX-10.84 6 ex10-84.htm Exhibit 10.84 EXHIBIT B LIFEMD, INC. DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT This Director and Officer Indemnification Agreement, dated as of January 3, 2023 (the “Agreement”), is made by and between LifeMD, Inc., a Delaware corporation (the “Company”), and Jessica Friedeman (the “Indemnitee”). RECITALS: A. The Delaware General Corporation Law provides that the busine
March 22, 2023	EX-3.1	Certificate of Incorporation, As Amended Exhibit 3.1
March 22, 2023	EX-4.5	LifeMD, Inc. Amended and Restated 2020 Equity and Incentive Plan Exhibit 4.5 LIFEMD, INC. AMENDED AND RESTATED 2020 EQUITY AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN: DEFINITIONS The name of the plan is the LIFEMD, INC. AMENDED AND RESTATED 2020 EQUITY AND INCENTIVE PLAN (the “Plan”). The purpose of the Plan is to encourage, retain and enable the officers, employees, directors, Consultants and other key persons of LIFEMD, INC., a Delaware corpora
February 10, 2023	EX-10.2	Restricted Stock Award Agreement, dated February 9, 2023, between LifeMD, Inc. and Joan LaRovere EX-10.2 3 ex10-2.htm Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT DIRECTORS THIS RESTRICTED STOCK AWARD (this “Agreement”) is granted as of February 9, 2023 (the “Grant Date”), and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the “Agreement”) between LifeMD, Inc. (the “Company”), and Dr. Joan LaRovere (the “Director”). WHEREAS, the Company desires to grant the Director, shares
February 10, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
February 10, 2023	EX-99.1	LifeMD Appoints Dr. Joan LaRovere to its Board of Directors Exhibit 99.1 LifeMD Appoints Dr. Joan LaRovere to its Board of Directors NEW YORK, February 10, 2023 — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Dr. Joan LaRovere to its Board of Directors. With Dr. LaRovere’s appointment, LifeMD’s Board will comprise nine directors, seven of whom are independent. “We are pleased to welcome Dr.
February 10, 2023	EX-2.1	Amendment to Stock Purchase Agreement, dated as of February 4, 2023, by and among Cleared Technologies, PBC, identified stockholders, and LifeMD, Inc. Exhibit 2.1 FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT between LIFEMD, INC., and CLEARED TECHNOLOGIES, PBC, and THE SELLERS LISTED ON SCHEDULE 1 OF THE AGREEMENT This FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT (the “Amendment”) is made effective as of February 4, 2023 (the “Effective Date”), between the Sellers identified on Schedule 1 of the Agreement (as defined below) (the “Sellers”) and Life
February 10, 2023	EX-10.3	Non-Qualified Stock Option Agreement, dated February 9, 2023, between LifeMD, Inc. and Joan LaRovere Exhibit 10.3 LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT DIRECTOR THIS NON-QUALIFIED STOCK OPTION is granted as of February 9, 2023 (the “Grant Date”), and reflected in this NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) by and between LifeMD, Inc. (the “Company”) and Dr. Joan LaRovere (the “Optionee”). WHEREAS, pursuant to the authority of the Board of Directors (the “Board”), the
February 10, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
February 10, 2023	EX-10.1	Director Agreement, dated February 9, 2023, between LifeMD, Inc. and Joan LaRovere EX-10.1 2 ex10-1.htm Exhibit 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of February 9, 2023 (the “Agreement”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), and Dr. Joan LaRovere, an individual with an address of [***] (the “Director”). WHEREAS, the Company and the Director desire to enter with respect to the appointment of the Director; WHEREAS, the Director
December 21, 2022	EX-10.1	Director Agreement, dated December 15, 2022, between LifeMD, Inc. and Kate Walsh Exhibit 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of December 15, 2022 (the ?Agreement?), by and between LifeMD, Inc., a Delaware corporation (the ?Company?), and Kate Walsh, an individual with an address of 5 Union Park Street, Boston, MA 02118 (the ?Director?). WHEREAS, the Company and the Director desire to enter with respect to the appointment of the Director; WHEREAS, the Dir
December 21, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 LIFEMD, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
December 21, 2022	EX-10.3	Non-Qualified Stock Option Agreement, dated December 15, 2022, between LifeMD, Inc. and Kate Walsh Exhibit 10.3 LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT DIRECTOR THIS NON-QUALIFIED STOCK OPTION is granted as of December 15, 2022 (the ?Grant Date?), and reflected in this NON-QUALIFIED STOCK OPTION AGREEMENT (this ?Agreement?) by and between LifeMD, Inc. (the ?Company?) and Kate Walsh (the ?Optionee?). WHEREAS, pursuant to the authority of the Board of Directors (the ?Board?), the Compan
December 21, 2022	EX-10.2	Restricted Stock Award Agreement, dated December 15, 2022, between LifeMD, Inc. and Kate Walsh Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT DIRECTORS THIS RESTRICTED STOCK AWARD (this ?Agreement?) is granted as of December 15, 2022 (the ?Grant Date?), and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the ?Agreement?) between LifeMD, Inc. (the ?Company?), and Kate Walsh (the ?Director?). WHEREAS, the Company desires to grant the Director, shares of the Company?s Common St
November 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 LIFEMD, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
November 14, 2022	EX-99.1	Presentation Material dated November 2022 Exhibit 99.1
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Ex
September 20, 2022	EX-99.1	LifeMD Appoints Bobby Jindal to the Board of Directors Exhibit 99.1 LifeMD Appoints Bobby Jindal to the Board of Directors NEW YORK, September 20, 2022 ? LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, is pleased to announce its appointment of Bobby Jindal, the 55th Governor of the State of Louisiana, to its board of directors. Mr. Jindal was elected as the nation?s youngest governor in 2007 and spent two terms as Louisian
September 20, 2022	EX-10.1	Director Agreement, dated September 14, 2022, between LifeMD, Inc. and Robert Jindal Exhibit 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of September 14, 2022 (the ?Agreement?), by and between LifeMD, Inc., a Delaware corporation (the ?Company?), and Robert Jindal, an individual with an address of 15040 Audubon Lakes Drive, Baton Rouge, LA 70810 (the ?Director?). WHEREAS, the Company and the Director desire to enter with respect to the appointment of the Director; W
September 20, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission Fil
September 20, 2022	EX-10.3	Non-Qualified Stock Option Agreement, dated September 14, 2022, between LifeMD, Inc. and Robert Jindal Exhibit 10.3 LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT DIRECTOR THIS NON-QUALIFIED STOCK OPTION is granted as of Sept. 14, 2022 (the ?Grant Date?), and reflected in this NON-QUALIFIED STOCK OPTION AGREEMENT (this ?Agreement?) by and between LifeMD, Inc. (the ?Company?) and Robert Jindal (the ?Optionee?). WHEREAS, pursuant to the authority of the Board of Directors (the ?Board?), the Compan
September 20, 2022	EX-10.2	Restricted Stock Award Agreement, dated September 14, 2022, between LifeMD, Inc. and Robert Jindal Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT DIRECTORS THIS RESTRICTED STOCK AWARD (this ?Agreement?) is granted as of Sept. 14, 2022 (the ?Grant Date?), and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the ?Agreement?) between LifeMD, Inc. (the ?Company?), and Robert Jindal (the ?Director?). WHEREAS, the Company desires to grant the Director, shares of the Company?s Common St
September 14, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File
September 14, 2022	EX-16.1	Letter from Friedman LLP, to the Securities and Exchange Commission, dated September 14, 2022 Exhibit 16.1 September 14, 2022, Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by LifeMD, Inc. under Item 4.01 of its Form 8-K dated September 14, 2022. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with other statements of LifeMD, Inc. contained therein.
August 17, 2022	424B3	LIFEMD INC. 809,139 Shares of Common Stock 35,369 Shares of Common Stock underlying Common Stock Purchase Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-250985 PROSPECTUS LIFEMD INC. 809,139 Shares of Common Stock 35,369 Shares of Common Stock underlying Common Stock Purchase Warrants This prospectus relates to the offering and resale by the Investors, the Placement Agent or their registered assigns (each a ?Selling Stockholder? and collectively the ?Selling Stockholders?) identified herein of
August 17, 2022	424B3	PROSPECTUS LIFEMD INC. 152,912 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-255586 PROSPECTUS LIFEMD INC. 152,912 Shares of Common Stock This prospectus relates to the offering and resale by the Investors or their registered assigns (each a ?Selling Stockholder? and collectively the ?Selling Stockholders?) identified herein of up to 152,912 shares of Common Stock of the Company, issued pursuant to that certain Securiti
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact n
July 1, 2022	POS AM	As filed with the Securities and Exchange Commission on July 1, 2022 As filed with the Securities and Exchange Commission on July 1, 2022 Registration No.
June 22, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num
May 13, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact
April 29, 2022	DEF 14A	LifeMD, Inc. Amended and Restated 2020 Equity and Incentive Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
March 28, 2022	POS AM	As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No.
March 7, 2022	EX-4.9	Description of Securities Exhibit 4.9 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is the description of each class of securities of LifeMD, Inc. (the ?Company?) outstanding as of December 31, 2021. The following description summarizes the most important terms of these securities. This summary does not purport to be complete and is qualified
March 7, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39785 LIFEMD, INC. (Exact na
March 7, 2022	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of LifeMD, Inc. Subsidiary Name Jurisdiction of Incorporation WorkSimpli Software, LLC Puerto Rico Conversion Labs PR LLC Puerto Rico

LFMD / LifeMD, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?